Workflow
赛力斯(601127) - 2023 Q3 - 季度财报
601127SERES(601127)2023-10-27 16:00

Financial Performance - The company's revenue for Q3 2023 was ¥5,647,781,028.60, representing a decrease of 47.25% compared to the same period last year[4]. - The net profit attributable to shareholders was -¥949,791,342.04, with a year-to-date net profit of -¥2,294,042,251.87[4]. - The company reported a basic and diluted earnings per share of -¥0.63 for Q3 2023, compared to -¥1.53 in the same period last year[5]. - The company experienced a significant decline in revenue due to a decrease in sales volume, but expects revenue to improve with the delivery of new models, such as the AITO M7 series launched in late September[7]. - Total operating revenue for the first three quarters of 2023 was CNY 16.68 billion, a decrease of 28.0% compared to CNY 23.12 billion in the same period of 2022[16]. - The net profit for Q3 2023 was negative CNY 3.45 billion, slightly improved from negative CNY 3.58 billion in Q3 2022[18]. - The company reported a total comprehensive income of negative CNY 3.44 billion for Q3 2023, compared to negative CNY 3.54 billion in Q3 2022[18]. - Basic earnings per share for Q3 2023 were negative CNY 1.53, an improvement from negative CNY 1.90 in Q3 2022[18]. Cash Flow and Liquidity - The net cash flow from operating activities increased by 147.59% in Q3 2023, amounting to ¥2,185,152,193.51, primarily due to an increase in product prepayments[5]. - The company anticipates continued improvement in cash flow from operating activities as product order deliveries increase[7]. - Net cash flow from operating activities for the first three quarters of 2023 was negative CNY 860 million, compared to positive CNY 1.20 billion in the same period of 2022[19]. - Cash received from operating activities totaled CNY 30.21 billion in the first three quarters of 2023, an increase of 8.9% from CNY 27.96 billion in the same period of 2022[19]. - Cash outflow from operating activities was CNY 31.07 billion in the first three quarters of 2023, up 16.0% from CNY 26.76 billion in the same period of 2022[19]. - The company achieved a cash inflow from investment activities of CNY 4.95 billion in the first three quarters of 2023, compared to CNY 1.97 billion in the same period of 2022[19]. Assets and Liabilities - Total assets at the end of the reporting period were ¥39,088,132,146.38, a decrease of 16.92% from the end of the previous year[5]. - The company's current assets totaled ¥19,330,499,469.96, down from ¥26,975,972,779.67, indicating a decrease of about 28.2%[13]. - The company's total liabilities were ¥32,585,633,985.84, reduced from ¥37,245,113,883.26, reflecting a decrease of approximately 12.0%[14]. - The company's cash and cash equivalents stood at ¥11,020,195,827.57, compared to ¥16,364,802,780.43, marking a decline of about 32.5%[12]. - Accounts receivable increased to ¥2,052,202,189.14 from ¥1,780,806,784.01, showing an increase of approximately 15.2%[13]. - The company's inventory decreased to ¥2,860,388,802.20 from ¥3,992,865,090.61, representing a decline of about 28.3%[13]. - Short-term borrowings rose to ¥2,347,375,638.90 from ¥2,078,656,419.46, indicating an increase of approximately 12.9%[14]. - The company's total equity attributable to shareholders decreased by 18.78% to ¥9,274,509,292.10 compared to the end of the previous year[5]. - The company's equity attributable to shareholders decreased to ¥9,274,509,292.10 from ¥11,419,671,239.52, reflecting a decline of about 18.8%[15]. Research and Development - Research and development expenses increased to CNY 1.09 billion in Q3 2023, up 20.4% from CNY 906.12 million in Q3 2022[17]. Shareholder Information - The company had 138,608 common shareholders at the end of the reporting period, with Chongqing Xiaokang Holding Co., Ltd. being the largest shareholder, holding 25.19% of the shares[8]. Other Information - The company has not disclosed any new product developments or market expansion strategies in the current report[10]. - The company did not apply new accounting standards for the current year[21].